MX2020001254A - Combinacion terapeutica de un inhibidor tirosina quinasa del egfr de tercera generacion y un inhibidor raf. - Google Patents
Combinacion terapeutica de un inhibidor tirosina quinasa del egfr de tercera generacion y un inhibidor raf.Info
- Publication number
- MX2020001254A MX2020001254A MX2020001254A MX2020001254A MX2020001254A MX 2020001254 A MX2020001254 A MX 2020001254A MX 2020001254 A MX2020001254 A MX 2020001254A MX 2020001254 A MX2020001254 A MX 2020001254A MX 2020001254 A MX2020001254 A MX 2020001254A
- Authority
- MX
- Mexico
- Prior art keywords
- inhibitor
- tyrosine kinase
- combination
- egfr tyrosine
- generation egfr
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Esta invención está relacionada con una combinación farmacéutica que comprende (a) un inhibidor de tirosina quinasa del EGFR de tercera generación y (b) un inhibidor Raf, en particular, para usarse en el tratamiento de un cáncer, en particular, un cáncer de pulmón. Esta invención también está relacionada con usos de dicha combinación para la preparación de un medicamento para el tratamiento de un cáncer; métodos para tratar un cáncer en un sujeto que los necesita que comprenden administrar a dicho sujeto una cantidad conjuntamente terapéuticamente eficaz de dicha combinación; composiciones farmacéuticas que comprenden dicha combinación y empaques comerciales para estas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762540595P | 2017-08-03 | 2017-08-03 | |
PCT/IB2018/055792 WO2019026007A1 (en) | 2017-08-03 | 2018-08-01 | THERAPEUTIC ASSOCIATION OF THIRD GENERATION TYFRSINE KINASE INHIBITOR AND RAF INHIBITOR |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020001254A true MX2020001254A (es) | 2020-03-20 |
Family
ID=63405289
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020001254A MX2020001254A (es) | 2017-08-03 | 2018-08-01 | Combinacion terapeutica de un inhibidor tirosina quinasa del egfr de tercera generacion y un inhibidor raf. |
Country Status (18)
Country | Link |
---|---|
US (1) | US20200237773A1 (es) |
EP (1) | EP3661516A1 (es) |
JP (1) | JP2020529411A (es) |
KR (1) | KR20200036880A (es) |
CN (1) | CN110996960A (es) |
AU (1) | AU2018311523A1 (es) |
BR (1) | BR112020001916A2 (es) |
CA (1) | CA3069564A1 (es) |
CL (1) | CL2020000270A1 (es) |
IL (1) | IL272350A (es) |
JO (1) | JOP20200014A1 (es) |
MX (1) | MX2020001254A (es) |
PH (1) | PH12020500096A1 (es) |
RU (1) | RU2020108192A (es) |
SG (1) | SG11201913249SA (es) |
TW (1) | TW201909920A (es) |
WO (1) | WO2019026007A1 (es) |
ZA (1) | ZA201908392B (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2022016496A (es) * | 2020-06-25 | 2023-02-22 | Tolremo Therapeutics Ag | Combinacion de un inhibidor del bromodominio cbp/p300 y un inhibidor del egfr para su uso en el tratamiento de la cpnm con mutacion del egfr. |
CN111991559B (zh) * | 2020-09-03 | 2022-03-22 | 中山大学 | 受体酪氨酸激酶抑制剂在制备预防和/或治疗新型冠状病毒感染药物中的应用 |
WO2023141659A2 (en) * | 2022-01-24 | 2023-07-27 | The Trustees Of Columbia University In The City Of New York | Targeting s100a9-aldh1a1-retinoic acid signaling to suppress brain relapse in egfr-mutant lung cancer |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JO3300B1 (ar) | 2012-06-06 | 2018-09-16 | Novartis Ag | مركبات وتركيبات لتعديل نشاط egfr |
AR092045A1 (es) * | 2012-08-07 | 2015-03-18 | Novartis Ag | Combinaciones farmaceuticas |
US9242969B2 (en) * | 2013-03-14 | 2016-01-26 | Novartis Ag | Biaryl amide compounds as kinase inhibitors |
UY36294A (es) * | 2014-09-12 | 2016-04-29 | Novartis Ag | Compuestos y composiciones como inhibidores de quinasa |
-
2018
- 2018-08-01 WO PCT/IB2018/055792 patent/WO2019026007A1/en unknown
- 2018-08-01 CN CN201880050143.XA patent/CN110996960A/zh active Pending
- 2018-08-01 JP JP2020505209A patent/JP2020529411A/ja active Pending
- 2018-08-01 EP EP18760056.4A patent/EP3661516A1/en not_active Withdrawn
- 2018-08-01 SG SG11201913249SA patent/SG11201913249SA/en unknown
- 2018-08-01 AU AU2018311523A patent/AU2018311523A1/en not_active Abandoned
- 2018-08-01 BR BR112020001916-0A patent/BR112020001916A2/pt not_active Application Discontinuation
- 2018-08-01 JO JOP/2020/0014A patent/JOP20200014A1/ar unknown
- 2018-08-01 US US16/634,924 patent/US20200237773A1/en not_active Abandoned
- 2018-08-01 CA CA3069564A patent/CA3069564A1/en not_active Abandoned
- 2018-08-01 MX MX2020001254A patent/MX2020001254A/es unknown
- 2018-08-01 KR KR1020207004658A patent/KR20200036880A/ko unknown
- 2018-08-01 RU RU2020108192A patent/RU2020108192A/ru not_active Application Discontinuation
- 2018-08-03 TW TW107127150A patent/TW201909920A/zh unknown
-
2019
- 2019-12-17 ZA ZA2019/08392A patent/ZA201908392B/en unknown
-
2020
- 2020-01-14 PH PH12020500096A patent/PH12020500096A1/en unknown
- 2020-01-29 IL IL272350A patent/IL272350A/en unknown
- 2020-01-30 CL CL2020000270A patent/CL2020000270A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
CL2020000270A1 (es) | 2020-08-28 |
AU2018311523A1 (en) | 2020-01-16 |
TW201909920A (zh) | 2019-03-16 |
US20200237773A1 (en) | 2020-07-30 |
SG11201913249SA (en) | 2020-02-27 |
PH12020500096A1 (en) | 2020-09-14 |
JP2020529411A (ja) | 2020-10-08 |
BR112020001916A2 (pt) | 2020-07-28 |
IL272350A (en) | 2020-03-31 |
ZA201908392B (en) | 2021-05-26 |
CN110996960A (zh) | 2020-04-10 |
JOP20200014A1 (ar) | 2022-10-30 |
EP3661516A1 (en) | 2020-06-10 |
WO2019026007A1 (en) | 2019-02-07 |
CA3069564A1 (en) | 2019-02-07 |
KR20200036880A (ko) | 2020-04-07 |
RU2020108192A (ru) | 2021-09-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12018500097A1 (en) | Combination of pd-1 antagonist with an egfr inhibitor | |
SA519402217B1 (ar) | مثبطات إيميدازو بيرازين لكيناز تيروسين بروتون | |
MX2019012884A (es) | Terapia de combinacion. | |
MX2021004639A (es) | Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos. | |
MX2019001920A (es) | Arn la terapia contra el cancer. | |
SG10201902664RA (en) | Combination therapy for treating cancer | |
PH12018500642A1 (en) | Anti-garp antibody | |
MX2021013830A (es) | Inhibidores de ezh2 para tratar linfomas. | |
EP4241850A3 (en) | Mdm2 inhibitors and combinations thereof | |
PH12020500099A1 (en) | Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a cyclin d kinase inhibitor | |
MX2020008258A (es) | Formulaciones pediátricas de niraparib y métodos de tratamiento pediátricos. | |
MX2016007351A (es) | Terapia de combinacion para tratar cancer. | |
JO3784B1 (ar) | الاستخدام المشترك للاجسمام المضادة pd-1 ومضادات m-csf في علاج السرطان | |
MX2015001122A (es) | Combinaciones farmaceuticas de un inhibidor de cdk4/6 y un inhibidor de b-raf. | |
EA201650134A1 (ru) | Специфическая сочетанная терапия злокачественных опухолей цитостатиком и его модификатором | |
WO2016109217A3 (en) | Btk inhibitors | |
PH12016502353A1 (en) | Pharmaceutical composition | |
PH12020500096A1 (en) | Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a raf inhibitor | |
WO2015095834A3 (en) | Cancer treatments using erk1/2 and bcl-2 family inhibitors | |
MX2019003134A (es) | Terapia de combinacion. | |
TW201613577A (en) | Pharmaceutical combinations | |
MA39765A (fr) | Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation | |
MX2021010041A (es) | Composiciones farmaceuticas que comprenden inhibidores de la proteina quinasa akt. | |
MX2021006156A (es) | Compuestos utiles en la terapia para el vih. | |
MX2019005104A (es) | Composiciones de zinc-y-pga y métodos para tratar el cancer. |